Tobacco Cell Or Cell Line, Per Se Patents (Class 435/414)
-
Publication number: 20130042373Abstract: The present invention is predicated, in part, on the functional characterisation of membrane bound proteins that contribute to cation flux across biological membranes. In accordance with the present invention, it has been determined that at least some PQ-loop repeat polypeptides contribute to cation flux across biological membranes.Type: ApplicationFiled: September 24, 2010Publication date: February 14, 2013Inventors: Mark Alfred Tester, Brent Kaiser, Scott Anthony William Carter, Monique Shearer, Darren Craig Plett, Stuart John Roy, Olivier Cotsaftis, Stephan Tyerman, Mamoru Okamoto
-
Publication number: 20130035233Abstract: The subject invention provides novel plants that are not only resistant to 2,4-D, but also to pyridyloxyacetate herbicides. Heretofore, there was no expectation or suggestion that a plant with both of these advantageous properties could be produced by the introduction of a single gene. The subject invention also includes plants that produce one or more enzymes of the subject invention “stacked” together with one or more other herbicide resistance genes. The subject invention enables novel combinations of herbicides to be used in new ways. Furthermore, the subject invention provides novel methods of preventing the development of, and controlling, strains of weeds that are resistant to one or more herbicides such as glyphosate. The preferred enzyme and gene for use according to the subject invention are referred to herein as AAD-12 (AryloxyAlkanoate Dioxygenase). This highly novel discovery is the basis of significant herbicide tolerant crop trait and selectable marker opportunities.Type: ApplicationFiled: October 8, 2012Publication date: February 7, 2013Applicant: Dow AgroSciences LLCInventor: Dow AgroSciences LLC
-
Publication number: 20130023012Abstract: Methods are provided for producing a vector that includes at least one spliceable intron. In the subject methods, intron containing vectors are produced from donor and acceptor vectors that each include a site specific recombinase site, where the subject donor and acceptor vectors further include splice donor and acceptor sites that, upon site specific recombination of the donor and acceptor vectors, define an intron in the product vector of the recombination step. Also provided are compositions for use in practicing the subject methods, including the donor and acceptor vectors themselves, as well as systems and kits that include the same. The subject invention finds use in a variety of different applications, including the production of expression vectors that encode C-terminal tagged fusion proteins, the production of expression vectors that encode pure protein and not a fusion thereof, and the like.Type: ApplicationFiled: July 23, 2012Publication date: January 24, 2013Applicant: LIFE TECHNOLOGIES CORPORATIONInventor: Andrew Alan Farmer
-
Publication number: 20130025005Abstract: The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.Type: ApplicationFiled: August 30, 2012Publication date: January 24, 2013Applicants: Novozymes A/S, Novozymes, Inc.Inventors: Debbie Yaver, Suzanne Otani, Janine Lin, Christopher Amolo, Kim Borch, Shamkant Anant Patkar, Michael Lamsa, Barbara Cherry
-
Publication number: 20130024956Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.Type: ApplicationFiled: September 14, 2012Publication date: January 24, 2013Applicants: PFIZER INC., AMGEN FREMONT INC.Inventors: Vahe Bedian, Ronald P. Gladue, Jose Corvalan, Xiao-Chi Jia, Xiao Feng
-
Publication number: 20130022539Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr115 antibodies. The invention encompasses a method of producing the anti-Ovr115 antibodies. Other aspects of the invention are a method of killing an Ovr115-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr115 antibody and a method of alleviating or treating an Ovr115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr115 antibody to the mammal.Type: ApplicationFiled: June 14, 2012Publication date: January 24, 2013Applicant: diaDexus, Inc.Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon
-
Publication number: 20130014293Abstract: The present invention relates to variants of a parent xylanase. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: ApplicationFiled: March 2, 2011Publication date: January 10, 2013Applicants: NOVOZYMES A/S, NOVOZYMES, INC.Inventors: Janine Lin, Jung Ye, Aubrey Jones, Suzanne Otani, Tia Heu, Pierre Cassland, Esben Friis
-
Publication number: 20130011878Abstract: The present invention provides compositions and methods relating to or derived from anti-PAR-2 antibodies. In particular embodiments, the invention provides human antibodies that bind PAR-2, PAR-2-binding fragments and derivatives of such antibodies, and PAR-2-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PAR-2-related disorders or conditions.Type: ApplicationFiled: June 25, 2012Publication date: January 10, 2013Applicant: AMGEN INC.Inventors: G. DUKE VIRCA, SHAW-FEN SYLVIA HU
-
Publication number: 20130005012Abstract: In vivo methods for production of styrene via a recombinant host cell can include cell expression of at least one polynucleotide encoding a polypeptide having cinnamic acid decarboxylase activity, and at least one polynucleotide encoding a polypeptide having phenylalanine ammonia lyase activity.Type: ApplicationFiled: June 22, 2012Publication date: January 3, 2013Applicant: PHYTOGENE, INC.Inventor: Xiaodan Yu
-
Publication number: 20120329709Abstract: The present invention provides methods and materials by which glycosylation of glycoproteins can be regulated. Methods include the monitoring and regulation of parameters such that a glycoprotein having a desired product quality is obtained.Type: ApplicationFiled: May 25, 2010Publication date: December 27, 2012Inventors: Brian Edward Collins, Tiffany Guo, Lakshmanan Thiruneelakantapillai, Kevin Millea, Dorota A. Bulik
-
Publication number: 20120331588Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: August 30, 2012Publication date: December 27, 2012Applicant: Novozymes A/SInventors: Alfredo Lopez de Leon, Michael Rey
-
Publication number: 20120331580Abstract: Compositions and methods for conferring hydroxyphenyl pyruvate dioxygenase (HPPD) herbicide resistance or tolerance to plants are provided. Compositions include amino acid sequences, and variants and fragments thereof, for mutant HPPD polypeptides. Nucleic acids that encode the mutant HPPD polypeptides are also provided. Methods for conferring herbicide resistance or tolerance, particularly resistance or tolerance to certain classes of herbicides that inhibit HPPD, in plants are further provided. Methods are also provided for selectively controlling weeds in a field at a crop locus and for the assay, characterization, identification and selection of the mutant HPPDs of the current invention that provide herbicide tolerance.Type: ApplicationFiled: August 13, 2012Publication date: December 27, 2012Inventors: Timothy Robert Hawkes, Michael Phillip Langford, Russell Colin Viner, Bernardus Theodorus Maria Vernooij, Richard Dale
-
Publication number: 20120321614Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit c-Met. The invention also relates to human anti-c-Met antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-c-Met antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-c-Met antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-c-Met antibodies.Type: ApplicationFiled: April 24, 2012Publication date: December 20, 2012Applicants: Pfizer, Inc., Amgen Fremont Inc.Inventors: Neil R. Michaud, Shama Kajiji, Gary Borzillo, Vahe Bedian, Kevin Coleman, Larry L. Green, Xiao-Chi Jia
-
Publication number: 20120321626Abstract: The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner.Type: ApplicationFiled: May 16, 2012Publication date: December 20, 2012Applicant: FABION PHARMACEUTICALS, INC.Inventor: Hongxing Zhou
-
Publication number: 20120324603Abstract: The invention relates to chimeric endonucleases, comprising an endonuclease and a heterologous DNA binding domain, as well as methods of targeted integration, targeted deletion or targeted mutation of polynucleotides using chimeric endonucleases.Type: ApplicationFiled: November 26, 2010Publication date: December 20, 2012Applicant: BASF Plant Sceience Company GmbHInventors: Andrea Hlubek, Christian Biesgen, Hans Wolfgang Höffken
-
Publication number: 20120322148Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic plants and animals.Type: ApplicationFiled: May 3, 2012Publication date: December 20, 2012Applicant: Intrexon CorporationInventors: Subba Reddy Palli, Marianna Zinovjevna Kapitskaya, Dean Ervin Cress
-
Publication number: 20120311739Abstract: Compositions and methods for conferring hydroxyphenyl pyruvate dioxygenase (HPPD) herbicide resistance or tolerance to plants are provided. Compositions include amino acid sequences, and variants and fragments thereof, for mutant HPPD polypeptides. Nucleic acids that encode the mutant HPPD polypeptides are also provided. Methods for conferring herbicide resistance or tolerance, particularly resistance or tolerance to certain classes of herbicides that inhibit HPPD, in plants are further provided. Methods are also provided for selectively controlling weeds in a field at a crop locus and for the assay, characterization, identification and selection of the mutant HPPDs of the current invention that provide herbicide tolerance.Type: ApplicationFiled: August 9, 2012Publication date: December 6, 2012Inventors: Timothy Robert Hawkes, Michael Phillip Langford, Russell Colin Viner, Bernardus Theodorus Maria Vernooij, Richard Dale
-
Publication number: 20120311740Abstract: Compositions and methods for conferring hydroxyphenyl pyruvate dioxygenase (HPPD) herbicide resistance or tolerance to plants are provided. Compositions include amino acid sequences, and variants and fragments thereof, for mutant HPPD polypeptides. Nucleic acids that encode the mutant HPPD polypeptides are also provided. Methods for conferring herbicide resistance or tolerance, particularly resistance or tolerance to certain classes of herbicides that inhibit HPPD, in plants are further provided. Methods are also provided for selectively controlling weeds in a field at a crop locus and for the assay, characterization, identification and selection of the mutant HPPDs of the current invention that provide herbicide tolerance.Type: ApplicationFiled: August 13, 2012Publication date: December 6, 2012Inventors: Timothy Robert Hawkes, Michael Phillip Langford, Russell Colin Viner, Bernardus Theodorus Maria Vernooij, Richard Dale
-
Publication number: 20120311738Abstract: Compositions and methods for conferring hydroxyphenyl pyruvate dioxygenase (HPPD) herbicide resistance or tolerance to plants are provided. Compositions include amino acid sequences, and variants and fragments thereof, for mutant HPPD polypeptides. Nucleic acids that encode the mutant HPPD polypeptides are also provided. Methods for conferring herbicide resistance or tolerance, particularly resistance or tolerance to certain classes of herbicides that inhibit HPPD, in plants are further provided. Methods are also provided for selectively controlling weeds in a field at a crop locus and for the assay, characterization, identification and selection of the mutant HPPDs of the current invention that provide herbicide tolerance.Type: ApplicationFiled: August 9, 2012Publication date: December 6, 2012Inventors: Timothy Robert Hawkes, Michael Phillip Langford, Russell Colin Viner, Bernardus Theodorus Maria Vernooij, Richard Dale
-
Publication number: 20120304335Abstract: Compositions and methods for conferring hydroxyphenyl pyruvate dioxygenase (HPPD) herbicide resistance or tolerance to plants are provided. Compositions include amino acid sequences, and variants and fragments thereof, for mutant HPPD polypeptides. Nucleic acids that encode the mutant HPPD polypeptides are also provided. Methods for conferring herbicide resistance or tolerance, particularly resistance or tolerance to certain classes of herbicides that inhibit HPPD, in plants are further provided. Methods are also provided for selectively controlling weeds in a field at a crop locus and for the assay, characterization, identification and selection of the mutant HPPDs of the current invention that provide herbicide tolerance.Type: ApplicationFiled: August 9, 2012Publication date: November 29, 2012Inventors: Timothy Robert Hawkes, Michael Phillip Langford, Russell Colin Viner, Bernardus Theodorus Maria Vernooij, Richard Dale
-
Publication number: 20120301947Abstract: A system for carbon fixation is provided. The system comprises enzymes which catalyze reactions of a carbon fixation pathway, wherein at least one of the reactions of the carbon fixation pathway is a carboxylation reaction, wherein products of the reactions of the carbon fixation pathway comprise oxaloacetate and malonyl-CoA, wherein an enzyme which performs the carboxylation reaction is selected from the group consisting of phophoenolpyruvate (PEP) carboxlase, pyruvate carboxylase and acetyl-CoA carboxylase and wherein an export product of the carbon fixation pathway is glyoxylate. Additional carbon fixation pathways are also provided and methods of generating same.Type: ApplicationFiled: February 10, 2011Publication date: November 29, 2012Applicant: Yeda Research and Development Co. Ltd.Inventors: Ron Milo, Arren Bar-Even, Elad Noor
-
Publication number: 20120301919Abstract: This invention relates to nucleic acid molecules comprising at least one nucleic acid sequence encoding for a peptide or protein of interest, at least one nucleic acid sequence encoding for a selectable marker, and at least one IRES sequence, wherein the at least one IRES sequence is located between the at least one nucleic acid sequence encoding for the peptide or protein of interest and the at least one nucleic acid sequence encoding for the selectable marker. Furthermore, this invention relates to host cells comprising such nucleic acid molecule and to methods of recombinant protein expression using such host cells.Type: ApplicationFiled: May 24, 2012Publication date: November 29, 2012Applicant: Agency for Science, Technology and ResearchInventors: Yuansheng Yang, Steven Ho, Jia Juan Lee
-
Publication number: 20120294865Abstract: The invention provides an integrin alpha-2 binding agent and methods of using an integrin alpha-2 binding agent to, e.g., inhibit proliferation of cancer cells, modulate tumor growth in a subject, inhibiting angiogenesis, or treating a fibrotic disorder. The invention further provides a method of producing an antibody, the method comprising propagating cancer cells in a 3-dimensional matrix; immunizing a mammal with the propagated cancer cells; and isolating an antibody from the immunized mammal. A method of identifying an agent that inhibits cancer cell proliferation also is provided.Type: ApplicationFiled: May 18, 2012Publication date: November 22, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Stephen J. Weiss, David T. Dudley
-
Publication number: 20120295354Abstract: Compositions and methods relating to the use of sulfonylurea-responsive repressors are provided. Compositions include polypeptides that specifically bind to an operator, wherein the specific binding is regulated by a sulfonylurea compound. Compositions also include polynucleotides encoding the polypeptides as well as constructs, vectors, prokaryotic and eukaryotic cells, and eukaryotic organisms including plants and seeds comprising the polynucleotide, and/or produced by the methods. Also provided are methods to provide a sulfonylurea-responsive repressor to a cell or organism, and to regulate expression of a polynucleotide of interest in a cell or organism, including a plant or plant cell.Type: ApplicationFiled: August 1, 2012Publication date: November 22, 2012Applicant: E. I. DU PONT DE NEMOURS AND COMPANY AND PIONEER HI-BRED INTERNATIONALInventors: Kevin E. McBride, Michael Lassner, Loren L. Looger, Brian McGonigle
-
Publication number: 20120282271Abstract: The invention provides methods and compositions for modulating hepsin activity and the MSP/Ron pathway, in particular by regulating pro-MSP activation by hepsin.Type: ApplicationFiled: October 21, 2010Publication date: November 8, 2012Applicant: Genentech, Inc.Inventors: Rajkumar Ganesan, Daniel Kirchhofer
-
Publication number: 20120284816Abstract: Plant metabolism and alkaloid levels can be regulated by transcription factors that regulate the nicotinic alkaloid biosynthetic pathway.Type: ApplicationFiled: May 4, 2012Publication date: November 8, 2012Inventors: Jonathan Page, Andrea T. Todd
-
Publication number: 20120270267Abstract: The present invention relates to alpha-amylase variants, polynucleotides encoding the variants and nucleic acid constructs, vectors, and host cells comprising the polynucleotides, and methods of using the variant enzymes.Type: ApplicationFiled: January 4, 2011Publication date: October 25, 2012Applicant: NOVOZYMES A/SInventors: Carsten Andersen, Thomas Agersten Poulsen
-
Publication number: 20120272400Abstract: The invention relates to methods of increasing the photosynthesis rate of a plant cell and/or the production of biomass in a plant, as well as to plant cells and plants with increased photosynthesis rate/production of biomass. The present invention also relates to a phosphatase of the light-harvesting complex of photosystem II, to nucleic acids coding for such phosphatase, and to mutants of such nucleic acids. Moreover, the present invention relates to plant cells and plants, wherein the activity of said phosphatase is inhibited; in particular the present invention relates to plant cells and plants comprising the mutant nucleic acids.Type: ApplicationFiled: October 29, 2010Publication date: October 25, 2012Inventors: Dario Leister, Mathias Pribil
-
Publication number: 20120263719Abstract: The present invention provides monoclonal antibodies specific for members of the Aspergillus genus and uses thereof for increasing the survival rate of a subject infected with an Aspergillus species. The present invention also provides conjugates of alliinase with monoclonal antibodies specific for members of the Aspergillus genus that preserve the ability of the antibody to recognize the fungus as well as the activity of the enzyme to produce cytotoxic molecules of allicin from the substrate alliin. The invention further provides pharmaceutical compositions comprising the conjugates of the mAbs of the invention and alliinase and uses thereof in combination with the substrate alliin in the treatment of diseases cause by Aspergillus species, in particular invasive aspergillosis.Type: ApplicationFiled: October 21, 2010Publication date: October 18, 2012Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.Inventors: David Mirelman, Aharon Rabinkov, Elena Appel
-
Publication number: 20120264686Abstract: Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.Type: ApplicationFiled: May 29, 2009Publication date: October 18, 2012Inventors: Thierry Guyon, Gilles Borrelly, Xavier Gallet, Lila Drittanti, Manuel Vega
-
Publication number: 20120258497Abstract: The present invention relates to alpha-amylase variants, polynucleotides encoding the variants and nucleic acid constructs, vectors, and host cells comprising the polynucleotides, and methods of using the variant enzymes.Type: ApplicationFiled: January 4, 2011Publication date: October 11, 2012Applicants: NOVOZYMES NORTH AMERICA, INC., NOVOZYMES A/SInventors: Carsten Andersen, Thomas Agersten Poulsen
-
Publication number: 20120255069Abstract: The present invention relates to a DNA fragment for improving translation efficiency, and a recombinant vector containing the same, and more specifically, to a DNA fragment which comprises any one nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-6, SEQ ID NOs: 8-10, SEQ ID NOs: 13 and 14 and SEQ ID NO: 16, and improves the translation efficiency of a heterologous protein placed in the downstream, and a recombinant vector containing the DNA fragment. The DNA fragment for improving translation efficiency according to the present invention and a recombinant vector containing the same can improve the translation of a heterologous protein in a transgenic plant.Type: ApplicationFiled: August 25, 2010Publication date: October 4, 2012Applicant: HELIX, CO., LIMITEDInventors: Yun Jeong Na, Eun Hyun Jeon, Eun Hye Kwon, Yong Woo Kim, Eun Ju Sohn, In Hwan Hwang
-
Publication number: 20120244131Abstract: A method for modulating double-strand break-induced mutagenesis at a genomic locus of interest in a cell, thereby giving new tools for genome engineering, including therapeutic applications and cell line engineering. A method for modulating double-strand break-induced mutagenesis, concerns the identification of effectors that modulate double-strand break-induced mutagenesis by use of interfering agents; these agents are capable of modulating double-strand break-induced mutagenesis through their respective direct or indirect actions on said effectors. Methods of using these effectors, interfering agents and derivatives, respectively, by introducing them into a cell in order to modulate and more particularly to increase double-strand break-induced mutagenesis. Specific derivatives of identified effectors and interfering agents, vectors encoding them, compositions and kits comprising such derivatives for modulating or increasing double-strand break-induced mutagenesis.Type: ApplicationFiled: February 6, 2012Publication date: September 27, 2012Applicant: CELLECTIS SAInventors: Fabien Delacote, Philippe Duchateau, Christophe Perez-Michaut
-
Publication number: 20120244569Abstract: Provided are methods for introducing a molecule of interest into a plant cell having a cell wall by using a QD-peptide conjugate having a quantum dot (QD) with one or more cell penetrating peptides (CPPs). Methods are provided for genetically or otherwise modifying plants and for treating or preventing disease in plant cells comprising a cell wall.Type: ApplicationFiled: March 22, 2012Publication date: September 27, 2012Applicant: DOW AGROSCIENCES LLCInventors: Jayakumar P. SAMUEL, Narasimha C. SAMBOJU, Kerrm Y. YAU, Gaofeng LIN, Steven R. WEBB, Frank BURROUGHS
-
Publication number: 20120244148Abstract: The present invention relates generally to the generation and characterization of neutralizing anti-IFN-? monoclonal antibodies with broad reactivity against various IFN-? subtypes. The invention further relates to the use of such anti-IFN-? antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-?, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).Type: ApplicationFiled: May 21, 2012Publication date: September 27, 2012Applicant: Genentech, Inc.Inventors: Anan Chuntharapai, Jin K. Kim, Leonard G. Presta, Timothy Stewart
-
Publication number: 20120244167Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.Type: ApplicationFiled: April 27, 2012Publication date: September 27, 2012Applicants: WARNER-LAMBERT COMPANY LLC, AMGEN FREMONT INC.Inventors: Vahe Bedian, Madhav Narasimha Devalaraja, Ian Foltz, Mary Haak-Frendscho, Sirid-Aimée Kellermann, Joseph Edwin Low, James Leslie Mobley
-
Publication number: 20120244578Abstract: The invention relates to monomeric Fc polypeptides and methods of making and using such polypeptides. The polypeptides comprise substitution of one or more hydrophobic interface residues in the CH3 region with a polar amino acid.Type: ApplicationFiled: November 22, 2010Publication date: September 27, 2012Applicant: AMGEN INC.Inventors: Gunasekaran Kannan, Hongxing Zhou, Nancy Sun
-
Publication number: 20120237972Abstract: The invention relates to the field of glycoprotein processing in transgenic plants used as cost efficient and contamination safe factories for the production of recombinant biopharmaceutical proteins or pharmaceutical compositions comprising these. The invention provides a plant comprising a functional mammalian enzyme providing N-glycan biosynthesis that is normally not present in plants, said plant additionally comprising at least a second mammalian protein or functional fragment thereof that is normally not present in plants.Type: ApplicationFiled: April 27, 2012Publication date: September 20, 2012Applicant: Stichting Dienst Landbouwkundig OnderzoekInventors: Hendrikus Antonius Cornelis Bakker, Hendrik Jan Bosch
-
Publication number: 20120230985Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.Type: ApplicationFiled: May 1, 2012Publication date: September 13, 2012Applicant: GENENTECH, INC.Inventors: LING-LING AN, SEK CHUNG FUNG, ROBERT F. KELLEY, HENRY B. LOWMAN, SANJAYA SINGH, HERREN WU
-
Publication number: 20120227134Abstract: A method for producing a plant with increased yield as compared to a corresponding wild type plant whereby the method comprises at least the following step: increasing or generating in a plant or a part thereof one or more activities of a polypeptide selected from the group consisting of 2-oxoglutarate-dependent dioxygenase, 3-ketoacyl-CoA thiolase, 3?-phosphoadenosine 5?-phosphate phosphatase, 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase, 5OS chloroplast ribosomal protein L21, 57972199. R01.1-protein, 60952769. R01.1-protein, 60S ribosomal protein, ABC transporter family protein, AP2 domain-containing transcription factor, argonaute protein, AT1 G29250.Type: ApplicationFiled: November 5, 2010Publication date: September 6, 2012Applicant: BASF PLANT SCIENCE COMPANY GMBHInventors: Hardy Schön, Oliver Thimm, Gerhard Ritte, Oliver Bläsing, Stefan Henkes, Koen Bruynseels, Yves Hatzfeld, Valerie Frankard, Ana Isabel Sanz Molinero, Christophe Reuzeau, Steven Vandenabeele, Bryan McKersie, Krishna Kolliparra, Christian Dammann
-
Publication number: 20120227132Abstract: The present invention provides polynucleotides and related polypeptides of the protein CNR. The invention provides genomic sequence for the CNR gene. CNR is responsible for controlling cell number.Type: ApplicationFiled: May 15, 2012Publication date: September 6, 2012Applicant: PIONEER HI BRED INTERNATIONAL INCInventors: Mei Guo, Carl R. Simmons, Howard P. Hershey
-
Publication number: 20120213787Abstract: The invention relates to storage-stable anti-TNFR1 antibody single variable domains (dAbs), antagonists and multispecific ligands, as well as methods and uses of these. The anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands are useful for treating and/or preventing inflammatory disease, such as arthritis or COPD, as well as for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient.Type: ApplicationFiled: October 25, 2010Publication date: August 23, 2012Inventors: Inusha De Silva, Armin Sepp, Adriaan Allart Stoop
-
Publication number: 20120210464Abstract: Improved compositions and methods for controlling pests are disclosed. In particular, novel engineered Cry1Ba (eCry1Ba) proteins having improved toxicity to lepidopteran insect pests are provided. By substituting at least one amino acid in domain I of a Cry1Ba protein an engineered Cry1Ba protein having substantially altered insecticidal properties is designed. Further, a method of making the engineered Cry1Ba proteins and methods of using the ecry1Ba nucleic acid sequences, for example in transgenic plants to express eCry1B proteins to confer protection from insect damage are disclosed.Type: ApplicationFiled: September 27, 2010Publication date: August 16, 2012Applicant: SYNGENTA PARTICIPATIONS AGInventors: Yan Gao, Jared Conville, Jeng Shong Chen
-
Publication number: 20120210469Abstract: Methods and means are provided for reducing the phenotypic expression of a nucleic acid of interest in eukaryotic cells, particularly in plant cells, by providing aberrant, preferably unpolyadenylated, target-specific RNA to the nucleus of the host cell. Preferably, the unpolyadenylated target-specific RNA is provided by transcription of a chimeric gene comprising a promoter, a DNA region encoding the target-specific RNA, a self-splicing ribozyme and a DNA region involved in 3? end formation and polyadenylation.Type: ApplicationFiled: April 22, 2011Publication date: August 16, 2012Applicant: Commonwealth Scientific and Industrial Research OrganisationInventors: Peter Michael WATERHOUSE, Ming-Bo Wang
-
Publication number: 20120202224Abstract: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.Type: ApplicationFiled: March 1, 2012Publication date: August 9, 2012Inventor: Leonard PRESTA
-
Publication number: 20120195901Abstract: Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described.Type: ApplicationFiled: April 16, 2012Publication date: August 2, 2012Inventors: Roger A. SABBADINI, William A. GARLAND, Genevieve HANSEN, James Stephen SWANEY
-
Publication number: 20120198584Abstract: The present invention includes expression cassettes that contain regulatory sequences derived from a target gene, for example, regulatory sequences from the HSP70, Ubi158, and Ubi361 genes, for expression of recombinant gene products in plants. Developmental expression profiling data were used to indentify several gene candidates for strong constitutive expression cassette development. Three expression cassettes were developed. They are based on the ZmHSP70, ZmUbi158, and ZmUBI361 genes.Type: ApplicationFiled: June 8, 2010Publication date: August 2, 2012Inventor: Michael L. Nuccio
-
Publication number: 20120171226Abstract: The present disclosure relates to anti-high molecular weight melanoma associated antigen (HMW-MAA) antibodies which bind to human HMW-MAA. Such antibodies may be used to treat diseases or disorders characterized by expression of HMW-MAA including cancer, for example, melanoma, basal cell carcinoma, ALL or AML.Type: ApplicationFiled: July 16, 2010Publication date: July 5, 2012Applicant: XOMA Technology Ltd.Inventor: Arnold H. Horwitz
-
Publication number: 20120156722Abstract: A full-length cDNA encoding novel proteins involved in the control of cell proliferation (human Gros1-L and S) was successfully isolated from the human testis cDNA libraries. A full-length cDNA encoding the mouse homologues of the human Gros1 (mouse Gros1-L and S) was also isolated. The colony forming activity of cells exogenously expressing Gros1-L was significantly reduced, while that of cells expressing Gros1 antisense RNA was significantly increased.Type: ApplicationFiled: February 22, 2012Publication date: June 21, 2012Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Renu Wadhwa, Takashi Sugihara, Akiko Ohide
-
Publication number: 20120142057Abstract: The present invention provides a method capable of producing a natural or recombinant protein in high yield. The present invention relates to a method of producing a polypeptide, comprising culturing a cell which strongly expresses cysteine sulfinic acid decarboxylase and has a transferred DNA encoding a desired polypeptide and thereby allowing the cell to produce the polypeptide. Hamster cysteine sulfinic acid decarboxylase, a DNA encoding the same, a recombinant vector and a transformed cell are also provided.Type: ApplicationFiled: February 8, 2012Publication date: June 7, 2012Inventors: Hisahiro Tabuchi, Satoshi Tainaka, Tomoya Sugiyama